The Multidisciplinary Association for Psychedelic Studies (MAPS) is honored to announce the election of Carl L. Hart, Ph.D., to MAPS’ Board of Directors, effective as of October 22, 2021. Dr. Carl Hart, …
Letters in Nature Medicine address important challenges in evaluating psychedelic-assisted therapies The recent publication of results of the first Phase 3 clinical trial of MDMA-assisted therapy for posttraumatic …
We encourage you to read and follow this page for detailed information regarding MAPS’ Therapy Code of Ethicsand our practices. You may safely and confidentially direct misconduct reports related to …
The Multidisciplinary Association for Psychedelic Studies (MAPS) and its wholly owned drug-development subsidiary MAPS Public Benefit Corporation (MAPS PBC) have entered into a Memorandum of Understanding …
Phase 2 clinical trial will compare the safety and efficacy of self-titrated high-THC cannabis against placebo for treatment of PTSD among Veterans Second clinical trial of inhaled botanical cannabis is …
Bill directs National Institute of Health (NIH) agencies to undertake and fund research into psychedelic-assisted therapies and potential benefits of cannabis, could accelerate the pace of research Special …
Fifty years after the War on Drugs was officially declared and psychedelic substance prohibition began in contravention of evidence supporting therapeutic use, the California State Senate has taken the …
California Senate Bill 519 decriminalizes the personal use and possession of psychedelic substances SB 519 will establish a task force to recommend regulatory systems California could adopt for safer personal …
Synergetic Press and the Multidisciplinary Association for Psychedelic Science (MAPS) are pleased to announce they have entered into a copublishing relationship effective May 1, 2021 which will greatly …
Phase 1 clinical trials of MDMA-assisted therapy for healthcare providers will measure development of self-compassion, professional quality of life, and professional burnout among clinicians delivering …
The highly statistically significant results and excellent safety record suggest MDMA-assisted therapy will be an effective treatment for severe, chronic PTSD 67% of participants who received three MDMA-assisted …
Widespread anecdotal reports of benefit have led to self-treatment of the symptoms of posttraumatic stress disorder (PTSD) with cannabis among Veterans and others; the safety and potential efficacy of …
